BriaCell Therapeutics Announces Pricing of $15 million Public Offering

Core Points - BriaCell Therapeutics Corp. announced a public offering of 12,000,000 units at a price of $1.25 per unit, aiming for gross proceeds of $15 million before expenses [1][3] - Each unit consists of one common share (or a Pre-Funded Warrant) and one Warrant, with the Warrant allowing the purchase of one common share at an exercise price of $1.50, expiring five years from issuance [1][3] - The offering is expected to close on July 16, 2025, subject to customary closing conditions [2] Financial Details - The net proceeds from the offering will be used for working capital, general corporate purposes, and advancing business objectives [3] - The offering is being facilitated by ThinkEquity as the sole placement agent [3] Regulatory Information - A registration statement on Form S-1 was filed with the SEC and became effective on July 15, 2025, with the offering being made only by means of a prospectus [4]